Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

BioCryst (BCRX) Stock Price & Analysis

BCRX Stock Chart & Stats

$8.47-$0.05(-0.59%)
At close: 4:00 PM EDT
$8$9$103 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
$8.38 - $8.62
52-Week Range
$6.23 - $11.22
Previous Close
$8.52
Volume
1.53M
Average Volume (3M)
5.08M
Market Cap
$2.16B
Enterprise Value
$3.14B
Total Cash (Recent Filing)
$352.57M
Total Debt (Recent Filing)
$409.86M
Price to Earnings (P/E)
―
Beta
0.60
Next Earnings
Nov 04, 2026 (Est.)
EPS Estimate
0.09
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Commercial Revenue Growth

Strong comparable revenue growth and continued ORLADEYO expansion indicate rising commercial adoption of BioCryst’s core therapy. Sustained product demand can support recurring revenue, fund development programs, and reinforce the company’s position in HAE over the next several quarters.

Cash Generation

Recent positive operating and free cash flow provides BioCryst with internally generated funding for commercialization and clinical development. This cash conversion is especially valuable because it can reduce reliance on external financing while supporting operations through upcoming product and trial milestones.

Pediatric Product Expansion

The pediatric pellet launch expands ORLADEYO’s addressable patient population and broadens the product’s utility across age groups. Early prescriptions and approval activity suggest initial commercial traction, creating an additional avenue for durable patient growth beyond the established capsule business.

Bears Say

Strained Balance Sheet

Persistently negative equity and meaningful debt leave BioCryst with limited balance-sheet cushion if operating conditions weaken. The capital structure may constrain financial flexibility, increase sensitivity to execution setbacks, and make it harder to fund future investments without relying on additional financing.

Volatile Profitability

The sharp swing from positive 2025 earnings to a substantial TTM loss shows that reported profitability is not yet consistently durable. Compressed gross margin and negative operating results could limit retained cash generation and reduce the resources available for sustained commercial and R&D investment.

Injectable Competition

Competitive pressure from newer injectable prophylactic treatments could make it harder for ORLADEYO to retain or expand its HAE share, even as the oral product grows. Patient switching may constrain future volume growth and require continued commercial investment to defend the franchise.

BioCryst News

BCRX FAQ

What was BioCryst’s price range in the past 12 months?
BioCryst lowest stock price was $6.23 and its highest was $11.22 in the past 12 months.
What is BioCryst’s market cap?
BioCryst’s market cap is $2.16B.
When is BioCryst’s upcoming earnings report date?
BioCryst’s next earnings report is estimated for Nov 04, 2026 (not yet confirmed), which is in 3 days.
How were BioCryst’s earnings last quarter?
BioCryst released its earnings results on Aug 05, 2026. The company reported $0.3 earnings per share for the quarter, beating the consensus estimate of $0.154 by $0.146.
Is BioCryst overvalued?
According to Wall Street analysts BioCryst’s price is currently Undervalued.
Does BioCryst pay dividends?
BioCryst does not currently pay dividends.
What is BioCryst’s EPS estimate?
BioCryst’s EPS estimate is 0.09.
How many shares outstanding does BioCryst have?
BioCryst has 255,535,110 shares outstanding.
What happened to BioCryst’s price movement after its last earnings report?
BioCryst reported an EPS of $0.3 in its last earnings report, beating expectations of $0.154. Following the earnings report the stock price went up 0.554%.
Which hedge fund is a major shareholder of BioCryst?
Hedge funds hold BioCryst shares: the largest hedge-fund position in BioCryst is 71,884,176 shares, and hedge funds increased their holdings by 5.0M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology